Our Story
Accencio® was started in 2017 by co-founders Kevin Brown and Kevin Brogle. They developed the foundational technologies for what would become Accencio while trying to solve research and discovery issues they observed while in large pharma. As an independent business, Accencio started as a tech-enabled services company utilizing the technologies in a consultative manner to support customers engaged in scientific research and/or intellectual property (IP) strategy initiatives.
The company’s most promising solution, IP-GeoScape®, was a first of its kind tool that allowed for the simultaneous understanding of molecule research and IP decision-making in one intuitive visualization. AI drug discovery companies soon began reaching out asking if access to the underlying IP-GeoScape algorithms was possible. What they and others noticed about IP-GeoScape was its ability to display many molecular structures and metadata without "falling apart" as traditional molecular landscaping tools do once the number of molecules increases substantially. These potential users began looking at IP-GeoScape as more than just a visual representation of molecular IP space; they saw it as a visual knowledge graph.
Today Accencio is preparing for the beta launch of its new platform for small molecules, antibodies, siRNAs, and genes. Customers will have the ability to use our proprietary data contextualization models to create AI-ready data sets and to generate high dimensional visual knowledge graphs. We are excited about the future.
Interested in learning more about our beta launch? Contact us here
